- /
- Supported exchanges /
- SHG /
- 688177.SHG
Bio-Thera Solutions Ltd (688177 SHG) stock market data APIs
Bio-Thera Solutions Ltd Financial Data Overview
Bio-Thera Solutions, Ltd., a biopharmaceutical company, researches and develops novel therapeutics for the treatment of cancer, autoimmune, cardiovascular, eye diseases, and other severe unmet medical needs in China and internationally. The company offers QLETLI for treatment of ankylosing spondylitis, rheumatoid arthritis, psoriasis, Crohn's disease, and uveitis; POBEVCY to treat patients with metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, persistent, recurrent, and metastatic cervical cancer; and BAT1806 for the treatment of rheumatoid arthritis, systemicjuvenile idiopathic arthritis, and cytokine release syndrome. It also develops BAT2206, a biosimilar drug candidate used to treat psoriasis, Crohn's disease, and ulcerative colitis; BAT2306 to treat plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis; and BAT4406F, BAT6026, BAT2606, and BAT2506 for treatment of various autoimmune diseases. In addition, the company develops BAT4306F, BAT1308, BAT1006, BAT4706, BAT6026, BAT6005, BAT6021, BAT7104, BAT8006, BAT8009, BAT8010, BAT8008, and BAT8007 for treatment of oncology; BAT2094 and BAT6024 to treat cardiovascular diseases; BAT5906 that is in Phase III clinical trial for the treatment for wet age-related macular degeneration (wAMD) and Phase II clinical trial for the treatment for diabetic macular edema (DME); and BAT2022 to treat respiratory infectious diseases. Bio-Thera Solutions, Ltd. was founded in 2003 and is headquartered in Guangzhou, China.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Bio-Thera Solutions Ltd data using free add-ons & libraries
Get Bio-Thera Solutions Ltd Fundamental Data
Bio-Thera Solutions Ltd Fundamental data includes:
- Net Revenue: 825 M
- EBITDA: -391 512 032
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2023-03-31
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Bio-Thera Solutions Ltd News
Bio-Thera and Richter Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, for EU countries, UK, Switzerland and other selected countries
GUANGZHOU, China and BUDAPEST, Hungary, Oct. 9, 2024 /PRNewswire/ -- Bio-Thera Solutions (688177:SH; "Bio-Thera"), a commercial-stage biopharmaceutical company developing a pipeline of innovative ther...
Bio-Thera Solutions and Biogen Publish Phase 3 Clinical Trial Data for TOFIDENCE™ (BAT1806/BIIB800), an approved Biosimilar referencing tocilizumab in Arthritis Research & Therapy
Comparable clinical efficacy and safety in Treatment Period 2 (TP2, Week 24-48) is maintained after switch from reference tocilizumab to TOFIDENCE (BAT1806/BIIB800) Phase 3 clinical data in totality d...
Bio-Thera Solutions Initiates Integrated Phase I / Phase III Clinical Trial for BAT3306, a Proposed Biosimilar of Keytruda® (Pembrolizumab)
GUANGZHOU, China, July 25, 2024 /PRNewswire/ -- Bio-Thera Solutions Inc. (688177: SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, today...
Bio-Thera Solutions Announces Regulatory Filing Acceptance for BAT2206, a Proposed Biosimilar to Stelara® in the US and EU
The U.S. Food and Drug Administration (FDA) has accepted Bio-Thera's Biologics License Applications (BLA) for BAT2206 as an interchangeable biosimilar to reference product Stelara® The European Medic...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.